Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Current local time in Porto-Novo (Africa/Porto-Novo timezone). Get information about the Africa/Porto-Novo time zone. Local time and date, DST adjusted (where ever daylight saving time is applicable) ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its weight loss program, which offers access to compounded semaglutide. Now ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best drug stocks to buy ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Porto Novo Business Private Limited is an Indian Non-Government Company. It's a private company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 1.0 lakhs and ...